RBC Capital Comments on on Regeneron Pharma (REGN) Primary Endpoint Data
Tweet Send to a Friend
RBC Capital analyst Kennen MacKay reiterated a Sector Perform rating and $628.00 price target on Regeneron Pharma (NASDAQ: REGN).The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
